Disease progression in amyotrophic lateral sclerosis (ALS) patients who received edaravone (Radicava) plus standard therapy of riluzole (Rilutek) did not differ from patients treated with standard ...

A virtual key opinion leader (KOL) and payer discussion was held on December 5, 2020. In attendance were 2 KOLs, both specialists in amyotrophic lateral sclerosis (ALS) at leading clinics in the ...

Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls. At 2 ...

Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a free radical scavenger that has shown potent antioxidant, anti-inflammatory and neuroprotective effects in variety of disease models. In this study ...

Long-term add-on treatment with intravenous (IV) edaravone is not associated with any change in the progression of amyotrophic lateral sclerosis (ALS), new research shows. These findings contradict ...

Review the side-effects of Edaravone as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

The Price section compares costs of the same generic drugs across brands and is purely for information purpose. Medindia neither buys nor sells drugs. Edaravone (Aravon) is prescribed for treating ...

A study of 137 patients found edaravone use lead to less functional loss than placebo, contrasting with results from a previous Phase 3 study which found no efficacy of the treatment over placebo.

Background Studies have shown that ischemia-reperfusion (I/R) produces free radicals leading to lipid peroxidation and damage to skeletal muscle. The purposes of this study were 1) to assess the ...

Edaravone, a medication that scrubs cells of toxic free radicals, may help a subset of people with amyotrophic lateral sclerosis. That was the upshot of a presentation at the International Symposium ...

Oral edaravone for patients with amyotrophic lateral sclerosis (ALS) is safe through a total of 144 weeks with no new safety signals observed. Among patients with amyotrophic lateral sclerosis (ALS), ...